Drug
Nal Iri
Nal Iri: highest development phase Phase 2, developed by Ipsen, Servier. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Ipsen, Servier
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nal-IRI NCT07028424 | Phase 2 | PDAC - Pancreatic Ductal Adenocarcinoma |
| nal-IRI NCT02551991 | Phase 2 | Pancreatic Cancer |
Latest
No recent events.
Follow Nal Iri on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.